First Interstate Bank Sells 52,361 Shares of Bristol Myers Squibb Company $BMY

Key Points

• First Interstate Bank cut its stake in Bristol Myers Squibb by 86.1%, selling 52,361 shares in Q4 and leaving it with 8,437 shares valued at about $455,000, signaling substantial institutional trimming.
• EVP David V. Elkins sold 30,000 shares on April 1 at an average price of $61.67 for roughly $1.85M, reducing his position by 15.85%; corporate insiders now own 0.05% of BMY.
• BMY missed Q4 EPS expectations ($1.26 vs. $1.65) while posting $12.5B in revenue, set FY2026 guidance of 6.05–6.35 EPS (consensus ~6.28), and declared a quarterly dividend of $0.63 (annualized yield ~4.3%, ex-dividend Apr 2, pay May 1).

First Interstate Bank lowered its holdings in Bristol Myers Squibb Company (NYSE:BMY - Free Report) by 86.1% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 8,437 shares of the biopharmaceutical company's stock after selling 52,361 shares during the period. First Interstate Bank's holdings in Bristol Myers Squibb were worth $455,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also added to or reduced their stakes in the company. Darwin Wealth Management LLC bought a new position in shares of Bristol Myers Squibb in the 2nd quarter valued at about $25,000. Harbor Capital Advisors Inc. grew its position in shares of Bristol Myers Squibb by 107.2% in the 3rd quarter. Harbor Capital Advisors Inc. now owns 605 shares of the biopharmaceutical company's stock valued at $27,000 after acquiring an additional 313 shares during the period. KERR FINANCIAL PLANNING Corp bought a new position in shares of Bristol Myers Squibb in the 3rd quarter valued at about $35,000. JPL Wealth Management LLC bought a new position in shares of Bristol Myers Squibb in the 3rd quarter valued at about $36,000. Finally, Beacon Financial Strategies CORP bought a new position in shares of Bristol Myers Squibb in the 4th quarter valued at about $38,000. Institutional investors own 76.41% of the company's stock.

Insider Activity

In other news, EVP David V. Elkins sold 30,000 shares of the firm's stock in a transaction dated Wednesday, April 1st. The shares were sold at an average price of $61.67, for a total transaction of $1,850,100.00. Following the completion of the sale, the executive vice president owned 159,248 shares in the company, valued at approximately $9,820,824.16. This trade represents a 15.85% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Corporate insiders own 0.05% of the company's stock.

Bristol Myers Squibb Stock Performance

NYSE BMY opened at $58.77 on Friday. The firm has a 50-day moving average of $59.69 and a 200-day moving average of $54.08. The company has a debt-to-equity ratio of 2.32, a quick ratio of 1.14 and a current ratio of 1.26. The stock has a market cap of $119.99 billion, a PE ratio of 17.03, a P/E/G ratio of 0.17 and a beta of 0.27. Bristol Myers Squibb Company has a 52-week low of $42.52 and a 52-week high of $62.89.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last posted its earnings results on Thursday, February 5th. The biopharmaceutical company reported $1.26 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.65 by ($0.39). The company had revenue of $12.50 billion for the quarter, compared to analyst estimates of $12.24 billion. Bristol Myers Squibb had a return on equity of 69.65% and a net margin of 14.64%.The business's quarterly revenue was up 1.3% compared to the same quarter last year. During the same quarter in the prior year, the business posted $1.67 EPS. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. On average, sell-side analysts anticipate that Bristol Myers Squibb Company will post 6.28 EPS for the current year.

Bristol Myers Squibb Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, May 1st. Stockholders of record on Thursday, April 2nd will be paid a dividend of $0.63 per share. This represents a $2.52 dividend on an annualized basis and a dividend yield of 4.3%. The ex-dividend date is Thursday, April 2nd. Bristol Myers Squibb's dividend payout ratio (DPR) is currently 73.04%.

Key Headlines Impacting Bristol Myers Squibb

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: BMY is being cited as a top defensive, low-volatility, high-yield holding for conservative portfolios, which supports demand from income-focused investors. Bristol-Myers Squibb Company (BMY): Favorite for Conservative Portfolios
• Positive Sentiment: Barclays reiterated a Buy on BMY, a near-term catalyst that can support the stock if positive analysts’ notes draw fresh buying interest. Bristol-Myers Squibb (BMY) Receives a Buy from Barclays
• Neutral Sentiment: Atrium Therapeutics announced it earned a $15M milestone from BMY under a cardiovascular collaboration — confirms ongoing R&D spend and pipeline partnering but is not material for BMY’s top-line. Atrium Therapeutics Earns $15 Million Milestone Payment
• Neutral Sentiment: Bernstein maintains a Hold on BMY — a reminder of mixed analyst views that can keep trading range-bound ahead of results. Bernstein Remains a Hold on Bristol-Myers Squibb (BMY)
• Negative Sentiment: Analysts and previews expect an earnings decline and flag that legacy drug declines and generic/competitive pressure could weigh on revenue — a key reason investors are cautious into Q1. Analysts Estimate Bristol Myers Squibb (BMY) to Report a Decline in Earnings
• Negative Sentiment: Seeking Alpha downgraded BMY from “Buy,” citing muted growth prospects despite a strong pipeline — sentiment that can pressure the stock if echoed by other shops. Bristol Myers Squibb: Strong Pipeline, Weak Outlook (Rating Downgrade)
• Negative Sentiment: BMY and Pfizer will make Eliquis available via Mark Cuban’s Cost Plus platform at a sharply lower transparent price — increases pricing scrutiny and could be viewed as a headwind for high-margin sales of a blockbuster drug. Bristol Myers, Pfizer Bring Eliquis to Cost Plus at $345 Monthly Business Wire: Eliquis via Mark Cuban Cost Plus

Analysts Set New Price Targets

A number of research analysts have recently commented on the stock. Bank of America decreased their price objective on shares of Bristol Myers Squibb from $68.00 to $67.00 and set a "buy" rating for the company in a research report on Thursday, April 9th. Wall Street Zen raised shares of Bristol Myers Squibb from a "buy" rating to a "strong-buy" rating in a research report on Sunday, April 19th. Leerink Partners lifted their price objective on shares of Bristol Myers Squibb from $54.00 to $60.00 and gave the company an "outperform" rating in a research report on Tuesday, January 13th. HSBC lifted their price objective on shares of Bristol Myers Squibb from $53.00 to $60.00 and gave the company a "hold" rating in a research report on Tuesday, March 17th. Finally, Piper Sandler reissued an "overweight" rating and issued a $75.00 price objective (up from $66.00) on shares of Bristol Myers Squibb in a research report on Monday, February 23rd. Eight research analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat, Bristol Myers Squibb currently has an average rating of "Hold" and a consensus target price of $61.31.

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company's core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS's marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.